Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes
This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.
1 . A method of preventing an increase in carotid intimal thickness in a patient diagnosed with a disease or condition selected from the group of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), early Type 2 diabetes, and Type 2 diabetes, comprising administering to said patient a therapeutically effective dosage of a long acting insulin.
2 . The method according to claim 1 wherein the long acting insulin is insulin glargine.
3 . The method according to claim 2 wherein the effective dosage is in the range of about 2 to about 150 IU per day.
4 . The method according to claim 3 wherein the effective dosage is in the range of about 2 to about 80 IU per day.
5 . The method according to claim 4 wherein the effective dosage is in the range of about 2 to about 40 IU per day.